- Home
- NVG vs CNTA Comparison
NVG vs CNTA Comparison
Compare NVG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NVG | CNTA |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NVG | CNTA |
|---|---|---|
| Price | $12.81 | $22.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 568.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 118.88 |
| 52 Week Low | $9.68 | $9.60 |
| 52 Week High | $12.21 | $30.58 |
Technical Indicators
Market Signals| Indicator | NVG | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 33.43 |
| Support Level | $12.55 | $21.55 |
| Resistance Level | $12.93 | $22.47 |
| Average True Range (ATR) | 0.08 | 0.96 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 77.66 | 16.65 |
Price Performance
Historical ComparisonAbout NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.